|
Veracyte is a private molecular diagnostics company founded in 2008. The company’s first product,
a definitive thyroid cancer diagnostic, is slated for commercialization in 2010. Our goal is to accurately
diagnose cancer to improve patient care.
Through the leadership of Bonnie Anderson, CEO and co-founder, our top tier executive team is made up of
professionals with track records of success in business and science. The company has filed several patents
for our technology and initiated IRB clinical trials across numerous academic and community sites. Our investors
have many years of experience in launching successful ventures in molecular diagnostics.
Veracyte is backed by premier bay area firms Kleiner Perkins Caufield & Byers (KPCB), TPG and Versant Ventures.
» Back to top
|
 |
The Veracyte Approach
Affirming Diagnoses with Molecular Cytology
Veracyte is developing a unique approach to the diagnosis of cancer using molecular biomarkers, which provide
more definitive information for better treatment decisions. We are pioneering the emerging field of molecular
cytology utilizing molecular biomarkers to resolve ambiguous test results found in traditional cytology.
Veracyte technology approaches the problem of ambiguous samples by analyzing the whole genome for markers of
benign and malignant diagnosis. This is a key difference in our approach to molecular diagnostics because it
goes beyond the traditional search for biomarkers.
The capacity to definitively diagnose cancer is based on our multi-center, prospective ongoing clinical
trials. These trials are able to reach a variety of populations employing both academic and community sites,
which differentiates our approach from others as we are able to unambiguously optimize our discovery and sample
collection methods.
» Back to top
|
|
Pipeline
Advancing Towards Definitive Diagnostics
Veracyte is advancing the development of diagnostics for thyroid cancer and non-small cell lung
cancer (NSCLC), areas which often have ambiguous diagnostic test results.
The development of the Thyroid Program consists of a whole genome approach, stringent clinical validation
trials, and a strong analytical tool suite. The whole genome approach allows us to characterize all the
possible molecular profiles that may exist in the general population through our samples. Our two clinical trials,
the largest ever undertaken in thyroid, currently are under way at 20 community and 10 academic medical centers.
The tools to analyze the data have been through a rigorous development of novel-learning algorithms and
statistical approaches. Adhering to these strict standards fosters the development of diagnostic tools that
we believe will be more accurate.
The Lung Program is presently at level Phase I Biomarker Discovery.
» Back to top
|
|
Bonnie Anderson, Chief Executive Officer
Bonnie Anderson is the co-founder of Veracyte and has served as Chief Executive Officer since 2008.
She has over 25 years of experience in venture capital consulting and market development services. Ms. Anderson
has served as Vice President-Director of the intrapreneurial Immunomics Operations at Beckman Coulter, and she
currently serves on the Board of Keck Graduate Institute of Life Sciences and the Advisory Board for Bay Bio.
Giulia C. Kennedy, Ph.D., Chief Scientific Officer, Senior Vice
President of Research and Development
Giulia C. Kennedy joined Veracyte in April 2008 and serves as
Chief Scientific Officer. With over 20 years of experience, she has led the Genomics Collaboration and Genotyping
Technology R & D groups at Affymetrix and was a scientific leader heading the Colon Cancer and Breast Cancer gene
discovery efforts at Chiron Corporation. Additionally, Dr. Kennedy has published over 40 articles in
peer-reviewed scientific journals.
Richard Lanman, M.D., Chief Medical Officer
Richard
Lanman joined Veracyte in 2008 as Chief Medical Officer. With over 25 years of experience, Dr. Lanman has been
involved in biotechnology as Executive Vice President and Chief Medical Officer of diaDexus, Inc., where he
developed and drove commercialization of PLAC™, a molecular diagnostic test for heart attack and stroke risk.
He has previously served as Executive Vice President of Corporate Development and Chief Medical Officer at
Atherotech, a cardiodiagnostics testing laboratory, and has served in similar capacities at the San Jose Medical
Group and Kaiser Permanente.
Anne Sissel, M.B.A., C.F.A., Senior Director of Finance and
Business Development
Anne Sissel joined Veracyte in 2009 as the Senior Director of Finance and Business
Development and has 10 years of experience in finance and investment banking. As an Investment Banker with
Goldman, Sachs & Co., Ms. Sissel focused on Mergers & Acquisitions and completed over 15 transactions including
the sale of Genentech to Roche, Qiagen’s acquisition of Digene, the sale of Ameripath to Quest, and
Johnson & Johnson’s acquisition of Guidant (terminated) and Pfizer Consumer Healthcare. She holds a B.S. in
Finance from Indiana University and an M.B.A. in Health Care Management from the Wharton School of the University
of Pennsylvania.
William Seltzer, Ph.D., F.A.C.M.G., Senior Vice President of
Laboratory Operations
William Seltzer joined Veracyte in November of 2009 as Senior Vice President
of Laboratory Operations. Dr. Seltzer is a board-certified clinical molecular geneticist with 24 years commercial
and academic experience in clinical diagnostic services, clinical diagnostic products development and
commercialization, quality assurance, and regulatory compliance. He has held several positions at Athena
Diagnostics, Inc., including Director of Laboratory Operations and Vice President, Quality Assurance and
Regulatory Affairs and Senior Laboratory Director.
» Back to top
|